Get the Daily Brief
Latest Biotech News
Parse and Graph aim to profile hundreds of millions of immune cells – an atlas for AI drug discovery
Parse Biosciences and Graph Therapeutics announced a strategic collaboration to build a large functional immune perturbation atlas by combining Graph’s patient‑derived disease models and...
Corxel closes $287M to advance oral GLP‑1 CX11 into pivotal testing
Corxel Pharmaceuticals raised $287 million in a Series D1 financing to accelerate development of CX11, an oral small‑molecule GLP‑1 receptor agonist targeting obesity and type 2 diabetes. The...
Genmab halts enrollment in early trial of ProfoundBio asset after acquisition
Genmab paused patient enrollment in its Phase 1/2 study of GEN1286, a candidate acquired through its $1.8 billion buyout of ProfoundBio, citing an operational hold on the trial. The stop affects a...
Catalent to close Gosselies cell therapy site – manufacturing realignment continues
Catalent confirmed plans to close its cell therapy site in Gosselies, Belgium, attributing the decision to changing market dynamics and customer needs. The company is considering transitioning...
Worldwide Clinical Trials buys Catalyst – Early‑phase oncology push
Worldwide Clinical Trials agreed to acquire UK-based Catalyst Clinical Research to bolster early‑phase oncology capabilities and add functional service provider (FSP) offerings. The buyer,...
Eclipsebio acquires Terrain Bio: RNA design meets sequencing analytics
Eclipsebio acquired Terrain Bio to add machine‑learning RNA design and analytics to its sequencing‑first RNA genomics stack. Eclipsebio said the deal accelerates its plan to offer an end‑to‑end...
Parse and Graph Therapeutics pair up... build massive immune perturbation atlas
Parse Biosciences and Graph Therapeutics announced a strategic partnership to build a large, functional immune perturbation atlas profiling hundreds of millions of human cells. Graph will run...
Fortitude launches GLUE‑DAC platform – ADCs with degrader payloads
Fortitude Biomedicines launched with seed financing to develop antibody‑drug conjugates that use targeted protein degraders as payloads (GLUE‑DAC). The Waltham, Mass., startup said the approach...
Corxel closes $287M — Funds oral GLP‑1 CX11 development
Corxel Pharmaceuticals closed a $287 million Series D1 financing to advance CX11, an oral small‑molecule GLP‑1 receptor agonist for obesity and type 2 diabetes. Investors included RTW Investments,...
Sarepta reframes Elevidys: three‑year durability claims amid safety debate
Sarepta released three‑year follow‑up data for Elevidys (delandistrogene moxeparvovec) suggesting durable functional benefits versus external historical controls. Company analyses show widening...
Drug pricing on trial and in policy: IRA petitions and insurer targeting
Two parallel forces are reshaping U.S. drug pricing: litigation against the Inflation Reduction Act’s price controls and fresh White House policy proposals targeting insurers. Multiple drugmakers,...
Diasorin inks Thermo Fisher pact: 15‑minute molecular PCR for US hospitals
Diasorin signed an exclusive U.S. distribution agreement with Fisher Scientific (Thermo Fisher) to place its Liaison NES rapid point‑of‑care qPCR system into hospitals. The device received FDA...
Catalent to close Belgium cell‑therapy site — raw‑material risks spotlighted
Catalent plans to close its Gosselies, Belgium cell‑therapy facility, citing changing market dynamics and customer needs. The move raises questions about capacity and access for cell therapy...
Genmab halts enrollment in ProfoundBio‑sourced cancer trial
Genmab stopped enrollment in an early‑stage Phase 1/2 study of GEN1286, a cancer candidate acquired through its $1.8 billion buyout of ProfoundBio. The study had targeted roughly 260 patients; the...
Sarepta reports three-year durability after gene therapy despite patient deaths
Sarepta Therapeutics released longer-term data showing durable effects three years after treatment with its Duchenne muscular dystrophy (DMD) gene therapy. The company presented findings from its...
Diasorin inks Thermo Fisher pact to push rapid POC qPCR into US hospitals
Diasorin signed an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific, to place its Liaison NES rapid point-of-care qPCR system into U.S. hospital channels....
Genmab halts enrollment in early cancer trial from ProfoundBio buyout
Genmab paused patient enrollment in an early‑stage trial of GEN1286, an oncology candidate acquired through its $1.8 billion purchase of ProfoundBio. The Phase 1/2 study had been planned to enroll...
Insilico secures FDA IND for Parkinson’s candidate ISM‑8969
Insilico Medicine Cayman Topco announced FDA clearance of an investigational new drug (IND) application for ISM‑8969, enabling initiation of a Phase I trial in healthy volunteers for a Parkinson’s...
Fortitude launches with seed cash to graft molecular glues onto ADCs
Fortitude Biomedicines closed a $13 million seed round to develop GLUE‑DACs—antibody‑drug conjugates that use molecular glue degraders as payloads—and advance a lead preclinical immune‑cell...
Corxel lands $287M to push oral GLP‑1 CX11 toward late‑stage trials
Corxel Pharmaceuticals closed a $287 million Series D1 financing to accelerate global development of CX11, an oral small‑molecule GLP‑1 receptor agonist targeting obesity and type 2 diabetes. The...